Extractable And Leachable Testing Market

How big is the Extractable and Leachable Testing Market in 2026?

USD 1.6 billion in 2026 and USD 4.5 billion by 2036 at a 10.8% CAGR.

Sales are projected to rise from USD 1.6 billion in 2026 to USD 4.5 billion by 2036 at a 10.8% CAGR. Pharmaceutical sponsors use outsourced testing services to connect material screening with stability evidence and toxicological interpretation across regulated product lifecycles.

Every new medicine uses a product-specific packaging or delivery configuration that requires compatibility evidence across regulated storage and patient-use conditions. FDA approved 46 novel drugs during 2025 across products entering distinct commercial configurations. Specialist analytical laboratory services convert these launches into packaging studies and stability-linked leachables monitoring.

Key Takeaways

• Demand rises as regulated product teams connect material screening with stability evidence and toxicological interpretation across development lifecycles.
• Extractable testing is projected to represent 42.0% of service demand in 2026 due to early material screening and analytical target selection.
• Pharmaceutical packaging is estimated to account for 38.0% of sample-type demand in 2026 owing to recurring container closure qualification.
• Chromatography-based analysis is forecast to capture 49.0% of technology demand in 2026 supported by broad volatile and non-volatile compound coverage.
• Matrix interference and unknown identification extend study schedules as laboratories develop methods for low-level compounds and stability samples.
• Eurofins Scientific SE, SGS SA, Intertek Group plc, WuXi AppTec Co., Ltd., Nelson Laboratories, LLC, Pace Life Sciences, LLC, Element Materials Technology and NAMSA serve regulated testing routes.

Analyst Perspective

"An E&L program loses commercial value if a laboratory reports unknown peaks without preserving signal changes across extraction and stability conditions. Laboratories gain an advantage by connecting compound identification with toxicological thresholds and material-change decisions so regulatory questions do not delay product programs."

- Nikhil Kaitwade, Principal Consultant, Future Market Insights

How is the Extractable and Leachable Testing Market segmented?

The extractable and leachable testing industry is segmented by service, sample type, application, end user, technology and region.

The market is organized by testing assignment, sample type, application, commissioning organization, analytical platform and region. Services cover extractable testing, leachable testing, method development and regulatory consulting for regulated product programs. Sample types include pharmaceutical packaging, medical devices, manufacturing systems and combination products requiring coordinated chemical studies. Applications span pharmaceuticals, biopharmaceuticals and medical devices. Commissioning organizations include drug companies and specialist research organizations. Technologies cover chromatography, spectroscopy, elemental analysis and other methods for difficult compound identification within medical device analytical testing programs.

What supports extractable testing within the service category?

Extractable studies establish worst-case compound profiles that guide material decisions ahead of regulated stability testing. Each profile guides healthcare regulatory affairs planning by defining targets and material risks that later leachables methods must address.

• Extractable testing is set to lead the service category with 42.0% share in 2026 due to early material screening and analytical target selection across regulated product programs.
• Material characterization and container closure studies identify volatile, non-volatile and elemental compounds ahead of long stability protocols. Leachable testing then measures product-specific migration under normal storage conditions across the proposed commercial shelf life.

Why does pharmaceutical packaging shape sample-type demand?

Packaging components remain in direct contact with drug products during regulated storage and commercial distribution. Glass containers, polymer systems and elastomeric closures require tailored extraction conditions as material composition changes compound profiles and analytical response.

• By sample type, pharmaceutical packaging is forecast to represent 38.0% in 2026 driven by recurring container closure qualification across launches and post-approval material changes.
• Medical devices require exposure-based chemical characterization for each contact route. bioprocessing systems need evidence across single-use bags, tubing and filtration workflows. Combination products add device and packaging interfaces that laboratories must evaluate within one coordinated protocol.

What makes pharmaceuticals central to the application category?

Pharmaceutical applications connect packaging compatibility with product stability and patient exposure across oral, injectable and ophthalmic formulations. Large molecule bioanalytical testing adds matrix complexity for biologics. Protein formulations change compound recovery and identification during low-level analysis.

• Based on application, pharmaceuticals are projected to account for 44.0% in 2026 due to recurring studies across regulated dosage forms and manufacturing components.
• Biopharmaceutical programs require low-level detection around sensitive proteins and single-use manufacturing equipment during extended stability studies. Medical-device applications align extraction conditions with contact duration and route so toxicologists estimate patient exposure accurately.

Why does chromatography-based analysis lead the technology category?

Chromatographic separation resolves complex mixtures so mass spectrometry identifies unknown compounds at low concentrations. Liquid chromatography systems support non-volatile analysis across complex samples requiring broad compound separation and low-level detection. Gas chromatography captures volatile and semi-volatile species requiring tailored extraction and preparation methods.

• The technology category is forecast to be led by chromatography-based analysis at 49.0% share in 2026 due to broad coverage of volatile and non-volatile regulated compounds.
• Spectroscopy and elemental analysis strengthen inorganic or molecular assessment with ICP-MS and FTIR methods. Difficult identifications unresolved by routine chromatographic screening require nuclear magnetic resonance or thermal analysis.

What are the drivers, restraints and opportunities in the Extractable and Leachable Testing Market?

Risk-based expectations increase connected E&L evidence demand as analytical uncertainty extends schedules and integrated programs reduce handoff losses.

• Driver: Risk-based guidance connects material knowledge with patient-exposure control and requires product-specific justification for extraction conditions and analytical thresholds.
• Restraint: Unknown compounds and matrix interference extend method development as stability-linked programs wait for scheduled samples and product-specific analytical decisions.
• Opportunity: Integrated laboratories retain compound histories across material screening, stability monitoring and toxicological assessment to reduce repeated interpretation during one product lifecycle.

Regulatory programs require a documented chain from material knowledge to measured patient exposure for each product. FDA issued draft ICH Q3E guidance in November 2025 for pharmaceutical products and regulated manufacturing components. The document defines a risk-based framework for product-specific extraction conditions and control decisions.

Matrix effects in complex formulations suppress analytical signals or produce unknown peaks that routine screens do not resolve. Additional separation work delays method validation and scheduled stability samples extend toxicological review across regulated product timelines.

Integrated laboratories retain compound histories across extractables screening, leachables monitoring and toxicological interpretation within one governed assignment. Closed system bioprocessing increases polymer component inventories. Laboratories preserving methods across stages answer product-specific questions without repeating earlier analytical work.

Which country CAGRs are profiled in the Extractable and Leachable Testing Market?

Country	CAGR
United States	10.4%
United Kingdom	10.3%
Germany	10.2%
Japan	10.1%
France	10.0%

How do country-level CAGRs compare in the Extractable and Leachable Testing Market?

The five approved country CAGRs span 0.4 percentage point across established pharmaceutical systems. These forecasts describe growth pace instead of current market size across the profiled countries.

• The United States defines the upper value as dense pharmaceutical development networks sustain mature external laboratory capacity.
• The United Kingdom is 0.1 percentage point lower as cross-border filing support balances separate national procedures.
• Germany occupies the midpoint as active manufacturing clusters face demanding method-transfer requirements.
• Japan remains close to Germany as structured regulator consultation offsets slow transfer across translated technical records.
• France closes the range at 10.0% and retains broad domestic pharmaceutical production coverage.

Comparable CAGRs can produce different market entry conditions. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

Country-wise Analysis

• United States sponsors use dense GMP laboratory networks to connect packaging studies with stability samples and toxicological review across injectable medicines, combination products and single-use manufacturing systems distributed nationwide. USP General Chapter <665> became official on May 1, 2026 and gives laboratories a defined qualification reference for plastic components used in pharmaceutical manufacturing across product-development and commercial production programs. Extractable and leachable testing in the United States is estimated to expand at 10.4% CAGR through 2036 as compendial clarity supports orders, although specialist capacity remains concentrated around major laboratory hubs and extends turnaround for sponsors operating outside those regions.
• United Kingdom sponsors coordinate packaging studies with domestic laboratories and regulatory specialists serving national filings, multinational stability programs and distributed manufacturing sites across several drug-delivery formats. MHRA opened consultation on draft ICH Q3E guidance in November 2025 and clarified the framework covering packaging, delivery systems and regulated manufacturing components used across complex product lifecycles. The United Kingdom's extractable and leachable testing outlook is anticipated to advance at 10.3% CAGR over the assessment period as coordinated study planning supports orders. Separate national and European procedures increase documentation work for multinational products and cross-border method transfers across regulated commercial supply networks.
• Germany combines pharmaceutical manufacturing clusters with European laboratory networks that transfer validated methods across domestic production sites, regional submissions and multisite quality systems serving broad regulated portfolios. Destatis reported a provisional 10.0% monthly increase in pharmaceutical output during May 2025 and provided a current workload signal for the country's established manufacturing base and specialist analytical testing demand. Germany is estimated to post 10.2% CAGR over the forecast period as active production supports testing orders, although demanding documentation and reproducibility requirements complicate method transfer across national and centralized European reviews for complex multisite products and stability programs serving several dosage forms.
• Japan sponsors rely on PMDA consultation routes and domestic analytical laboratories to coordinate packaging studies across local development portfolios, imported reference materials and multinational manufacturing programs requiring translated technical records. PMDA opened comments on draft ICH Q3E guidance in September 2025 and scheduled an October briefing for domestic development and specialist laboratory teams planning complex regulated testing studies. Extractable and leachable testing demand in Japan is forecast to rise at 10.1% CAGR over the forecast period. Translated dossiers and cross-border method transfers extend coordination between domestic and global sites serving complex multinational products worldwide.
• France supports regulated pharmaceutical development with domestic manufacturing sites and European laboratory networks that coordinate stability evidence across national products, cross-border submissions and distributed production programs serving several dosage forms. The industry ministry reported 260 pharmaceutical laboratories across more than 400 industrial sites in May 2026 and confirmed a broad operating base for development, production and specialist regulated analytical assignments. Extractable and leachable testing sales in France are forecast to expand at 10.0% CAGR by 2036 as domestic activity supports orders, although lengthy stability schedules and uneven specialist toxicology access delays completion across national and multinational regulated product programs.

Who are the notable companies in the Extractable and Leachable Testing Market?

Eurofins Scientific SE, SGS SA, Intertek Group plc, WuXi AppTec Co., Ltd., Nelson Laboratories, LLC, Pace Life Sciences, LLC, Element Materials Technology and NAMSA are the notable companies serving this market.

Global laboratory networks compete with specialist pharmaceutical laboratories and medical-device chemistry providers in a moderately fragmented field with demanding qualification barriers. Medical-device manufacturers value laboratories that connect preclinical medical device testing with chemical characterization and toxicological review. Pharmaceutical sponsors compare similar continuity across healthcare analytical testing programs serving packaging and stability assignments.

• Eurofins Scientific SE, SGS SA and Intertek Group plc operate multinational laboratory networks serving pharmaceutical and medical-device programs.
• WuXi AppTec Co., Ltd., Nelson Laboratories, LLC and NAMSA combine chemical characterization with toxicological or regulatory support for medical devices and combination products.
• Pace Life Sciences, LLC and Element Materials Technology support pharmaceutical programs with extractables studies, leachables stability work and method development.

Competitive Benchmarking: Extractable and Leachable Testing Market

Company	Full E&L Study Breadth	Toxicology and Regulatory Support	Pharmaceutical and Medical Device Coverage	Geographic Reach
Eurofins Scientific SE	High	High	High	Global
SGS SA	High	High	High	Global
Intertek Group plc	High	High	High	Global
WuXi AppTec Co., Ltd.	Medium	High	High	China with global client support
Nelson Laboratories, LLC	High	High	High	North America, Europe and Asia
Pace Life Sciences, LLC	High	Medium	High	North America
Element Materials Technology	High	High	High	Global
NAMSA	Medium	High	Low	United States and Europe

Scoring basis: Full E&L Study Breadth is High for several material classes with stability support. Medium covers a narrower direct program and Low covers one documented study stage. Toxicology and Regulatory Support is High for risk interpretation plus submission support. Medium covers one function and Low covers analytical testing without either function. Pharmaceutical and Medical Device Coverage is High across both regulated product groups. Medium covers one group plus combination products and Low covers one group. Geographic Reach records current laboratory or client coverage without converting absent evidence into a Low rating.

Key Developments in the Extractable and Leachable Testing Market

• In October 2025, Intertek launched extractables and leachables testing at its GMP laboratory in Reinach for pharmaceutical products subject to new Korean Pharmacopeia requirements. The service connects method development and toxicological assessment with a mandatory compliance route for new and imported medicines.
• In February 2025, NAMSA completed its acquisition of WuXi AppTec's United States medical-device testing operations. The transaction expanded E&L laboratory capacity alongside biocompatibility and regulatory consulting for manufacturers requiring coordinated biological safety programs.
• In January 2025, Nelson Labs installed two Dual-LC Orbitrap Exploris 120 systems at its Leuven laboratory for non-volatile extractables and leachables screening. The upgrade increased compound-identification sensitivity and instrument capacity without changing established screening principles.

Key Players in the Extractable and Leachable Testing Market

Global Testing Networks

• Eurofins Scientific SE
• SGS SA
• Intertek Group plc

Integrated Life Sciences Laboratories

• WuXi AppTec Co., Ltd.
• Pace Life Sciences, LLC
• Element Materials Technology

Medical Device E&L Specialists

• Nelson Laboratories, LLC
• NAMSA

Extractable and Leachable Testing Market - Report Scope

Coverage field	Report scope
Market breakdown	By service, sample type, application, end user, technology and region.
Quantitative Units	USD billion.
Market Definition	Commercial extractable and leachable testing services used to evaluate regulated packaging, devices, manufacturing systems and combination products.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	United States, United Kingdom, Germany, Japan, France, and 20+ countries included in the full report.
Key Companies Profiled	Eurofins Scientific SE, SGS SA, Intertek Group plc, WuXi AppTec Co., Ltd., Nelson Laboratories, LLC, Pace Life Sciences, LLC, Element Materials Technology and NAMSA.
Forecast Period	2026 to 2036.
Approach	Primary and secondary research with market triangulation.

Extractable and Leachable Testing Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Extractable and Leachable Testing Market by Segments

Extractable and Leachable Testing Market segmented by Service:

• Extractable Testing
  • Material Characterization
  • Container Closure System Testing
  • Single-use System Testing
• Leachable Testing
  • Stability Leachable Studies
  • Routine Leachable Monitoring
  • Targeted Leachable Analysis
• Analytical Method Development
  • Method Validation
  • Method Optimization
  • Reference Standard Development
• Consulting & Regulatory Services
  • Risk Assessment
  • Regulatory Documentation
  • Compliance Support

Extractable and Leachable Testing Market segmented by Sample Type:

• Pharmaceutical Packaging
  • Glass Containers
  • Polymer Containers
  • Elastomeric Closures
• Medical Devices
  • Implantable Devices
  • Drug Delivery Devices
  • Disposable Medical Devices
• Biopharmaceutical Manufacturing Systems
  • Single-use Bags
  • Tubing & Connectors
  • Filtration Systems
• Combination Products
  • Prefilled Syringes
  • Auto-injectors
  • Inhalation Devices

Extractable and Leachable Testing Market segmented by Application:

• Pharmaceuticals
  • Oral Drug Products
  • Injectable Drug Products
  • Ophthalmic Products
• Biopharmaceuticals
  • Monoclonal Antibodies
  • Cell & Gene Therapies
  • Vaccines
• Medical Devices
  • Implantable Devices
  • Diagnostic Devices
  • Drug-device Combination Products

Extractable and Leachable Testing Market segmented by End User:

• Pharmaceutical Companies
  • Innovator Companies
  • Generic Manufacturers
  • Specialty Pharma Companies
• Biotechnology Companies
  • Biologics Developers
  • Cell & Gene Therapy Companies
  • Biosimilar Developers
• Contract Research Organizations
  • Analytical Testing Laboratories
  • Contract Development Organizations
  • Clinical Research Organizations

Extractable and Leachable Testing Market segmented by Technology:

• Chromatography-based Analysis
  • Gas Chromatography-Mass Spectrometry
  • Liquid Chromatography-Mass Spectrometry
  • High-performance Liquid Chromatography
• Spectroscopy & Elemental Analysis
  • Inductively Coupled Plasma-Mass Spectrometry
  • Fourier Transform Infrared Spectroscopy
  • Ultraviolet-visible Spectroscopy
• Other Analytical Techniques
  • Nuclear Magnetic Resonance
  • Headspace Analysis
  • Thermal Analysis

Extractable and Leachable Testing Market by Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
  • Western Europe
• Germany
  • United Kingdom
  • Italy
  • Spain
  • France
  • Nordics
  • Benelux
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan and Baltic States
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union Countries
  • Rest of Middle East and Africa

Research Sources and Bibliography

• USA Food and Drug Administration. (2026). Novel Drug Approvals for 2025.
• USA Food and Drug Administration. (2025, November). Q3E Guideline for Extractables and Leachables.
• United States Pharmacopeia. (2026, May 1). USP solutions to solve your challenges with Extractables and Leachables.
• Medicines and Healthcare products Regulatory Agency. (2025, November 19). Consultation on the International Council for Harmonisation Guideline Q3E for Extractables and Leachables.
• Federal Statistical Office of Germany. (2025, July 7). Production in May 2025: +1.2% on the previous month.
• Pharmaceuticals and Medical Devices Agency. (2025, September 22). ICH Q3E
• Direction générale des Entreprises. (2026, May 26). La filière santé.
• Intertek Group plc. (2025, October 1). Intertek Pharmaceutical Services launches expert extractables and leachables testing services for compliance with new Korean Pharmacopeia requirements.
• NAMSA. (2025, March 3). NAMSA completes acquisition of WuXi AppTec US medical device testing business.
• Nelson Laboratories, LLC. (2025, January 28). Nelson Labs Leuven unveils analytical upgrade for non-volatile extractables and leachables screening.
• Eurofins Medical Device Services. (2026, May 12). Building what’s next in MedTech.
• SGS SA. (2024, March). How to get ready for new General USP Chapters <665> and <1665>.
• WuXi AppTec Co., Ltd. (2026, May 25). 2nd Annual Extractables & Leachables 2026 Webinar.
• Element Materials Technology. (2024, March 21). Element launches rapid response pharmaceutical testing service.
• Nelson Laboratories, LLC. (2025, April 17). Nelson Labs celebrates 40 years of excellence in science and service.
• NAMSA. (2026, January 8). NAMSA announces strategic acquisition of select assets of Labcorp’s early development medical device testing business.
• Pace Life Sciences. (2025, July 29). Pace Life Sciences achieves fourth consecutive positive FDA inspection.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the extractable and leachable testing market in 2026 and 2036?
• Which operating conditions support demand for extractable and leachable testing services?
• Which service category accounts for the largest 2026 share?
• How does sample type influence study design and laboratory selection?
• Which application category supports recurring testing assignments?
• Which analytical technology provides broad compound coverage?
• How do country growth rates differ across the profiled market set?
• Which companies provide pharmaceutical and medical-device E&L services?